Free radicals, antioxidant defense systems, and schizophrenia
暂无分享,去创建一个
[1] Takayuki Obata,et al. Negative Correlation between Brain Glutathione Level and Negative Symptoms in Schizophrenia: A 3T 1H-MRS Study , 2008, PloS one.
[2] M. Phillips,et al. Increased pentane and carbon disulfide in the breath of patients with schizophrenia. , 1993, Journal of clinical pathology.
[3] B. Harvey,et al. Haloperidol-induced dyskinesia is associated with striatal NO synthase suppression: Reversal with olanzapine , 2003, Behavioural pharmacology.
[4] L. Qi,et al. The novel oxidative stress marker thioredoxin is increased in first-episode schizophrenic patients , 2009, Schizophrenia Research.
[5] D. Sorescu,et al. Modulation of Protein Kinase Activity and Gene Expression by Reactive Oxygen Species and Their Role in Vascular Physiology and Pathophysiology , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[6] W. Carpenter. The deficit syndrome. , 1994, The American journal of psychiatry.
[7] J. Lieberman,et al. Oxidative stress in tardive dyskinesia: Genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[8] E. Lander,et al. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease , 2003, Nature Genetics.
[9] S. Mukherjee,et al. Enzymes of the antioxidant defense system in chronic schizophrenic patients , 1991, Biological Psychiatry.
[10] F. Kapczinski,et al. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: A study of patients treated with haloperidol or clozapine , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[11] T. Shinkai,et al. Manganese Superoxide Dismutase Gene Polymorphism and Schizophrenia: Relation to Tardive Dyskinesia , 2000, Neuropsychopharmacology.
[12] Yan Shen,et al. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics , 2006, Schizophrenia Research.
[13] D. Jeste,et al. Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms. , 1988, Schizophrenia bulletin.
[14] J. Deleuze,et al. Association between the MnSOD Ala-9Val polymorphism and development of schizophrenia and abnormal involuntary movements in the Xhosa population , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[15] T. Kosten,et al. Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia. , 2007, The Journal of clinical psychiatry.
[16] T. Woo,et al. Oxidative stress in schizophrenia: An integrated approach , 2011, Neuroscience & Biobehavioral Reviews.
[17] K. Uğurbil,et al. Validation of glutathione quantitation from STEAM spectra against edited 1H NMR spectroscopy at 4T: application to schizophrenia , 2005, Magnetic Resonance Materials in Physics, Biology and Medicine.
[18] G. Reynolds,et al. Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment , 1993, International clinical psychopharmacology.
[19] Vitamin E treatment of tardive dyskinesia. , 1993, The American journal of psychiatry.
[20] K. Davies. Oxidative stress: the paradox of aerobic life. , 1995, Biochemical Society symposium.
[21] Alin Ciobica,et al. Oxidative stress in schizophrenia - focusing on the main markers. , 2011, Psychiatria Danubina.
[22] Paul J. Harrison,et al. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence , 2005, Molecular Psychiatry.
[23] Matcheri Keshavan,et al. Reduced plasma antioxidants in first-episode patients with schizophrenia , 2003, Schizophrenia Research.
[24] P. Ranjekar,et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients , 2003, Psychiatry Research.
[25] A. Kling,et al. Glutathione peroxidase and CT scan abnormalities in schizophrenia , 1987, Biological Psychiatry.
[26] Michael Berk,et al. Medial temporal lobe glutathione concentration in first episode psychosis: A 1H-MRS investigation , 2009, Neurobiology of Disease.
[27] Yong-Ku Kim,et al. Reduced plasma nitric oxide metabolites before and after antipsychotic treatment in patients with schizophrenia compared to controls , 2008, Schizophrenia Research.
[28] B. Halliwell,et al. Biochemistry of oxidative stress. , 2007, Biochemical Society transactions.
[29] G. Meredith,et al. Elevated neuronal nitric oxide synthase expression in chronic haloperidol-treated rats , 2003, Neuropharmacology.
[30] A. Kling,et al. Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT scan abnormalities: Relation to psychosocial variables , 1990, Psychiatry Research.
[31] T. Kosten,et al. Association of the manganese superoxide dismutase gene Ala–9Val polymorphism with clinical phenotypes and tardive dyskinesia in schizophrenic patients , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[32] R. Chan,et al. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. , 2011, The Journal of clinical psychiatry.
[33] T. Lockwood,et al. Redox control of protein degradation. , 2000, Antioxidants & redox signaling.
[34] T. Kosten,et al. Elevated plasma superoxide dismutase in first-episode and drug naive patients with schizophrenia: Inverse association with positive symptoms , 2012, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[35] D. Kammen,et al. Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. , 1998, Journal of psychiatric research.
[36] Jeffrey K. Yao,et al. Reduced level of plasma antioxidant uric acid in schizophrenia , 1998, Psychiatry Research.
[37] H. Herken,et al. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia , 2001, Molecular Psychiatry.
[38] Abraham Nyska,et al. Invited Review: Oxidation of Biological Systems: Oxidative Stress Phenomena, Antioxidants, Redox Reactions, and Methods for Their Quantification , 2002, Toxicologic pathology.
[39] H. Lal,et al. Oxidative stress and role of antioxidant and ω-3 essential fatty acid supplementation in schizophrenia , 2001, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[40] Brown Ja,et al. Free radical involvement in neuropsychiatric illnesses. , 1995 .
[41] X. Zhang,et al. The Effect of Risperidone Treatment on Superoxide Dismutase in Schizophrenia , 2003, Journal of clinical psychopharmacology.
[42] H. Holcomb,et al. Phenotype of schizophrenia: a review and formulation , 2005, Molecular Psychiatry.
[43] Bernhard Bogerts,et al. The many faces of nitric oxide in schizophrenia. A review , 2005, Schizophrenia Research.
[44] J. Castro-Fornieles,et al. Reduced antioxidant defense in early onset first-episode psychosis: a case-control study , 2011, BMC psychiatry.
[45] Ravinder Reddy,et al. Altered Glutathione Redox State in Schizophrenia , 2005, Disease markers.
[46] T. Shinkai,et al. Genetic association analysis of the glutathione peroxidase (GPX1) gene polymorphism (Pro197Leu) with tardive dyskinesia , 2006, Psychiatry Research.
[47] F. Tarazi,et al. Long-term effects of newer antipsychotic drugs on neuronal nitric oxide synthase in rat brain. , 2002, Nitric oxide : biology and chemistry.
[48] T. Kosten,et al. Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[49] E. Stadtman,et al. Free radical-mediated oxidation of free amino acids and amino acid residues in proteins , 2003, Amino Acids.
[50] P Boesiger,et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo , 2000, The European journal of neuroscience.
[51] A. Kerkeni,et al. Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients , 2011, BMC psychiatry.
[52] R. Buzina,et al. Vitamin C status in chronic schizophrenia , 1990, Biological Psychiatry.
[53] G. Konat. H2O2-induced higher order chromatin degradation: A novel mechanism of oxidative genotoxicity , 2003, Journal of Biosciences.
[54] Etelvino J. H. Bechara,et al. Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients. , 1986, Clinical chemistry.
[55] H. Herken,et al. A Defect in the Antioxidant Defense System in Schizophrenia , 2009, Neuropsychobiology.
[56] J. Lohr. Oxygen radicals and neuropsychiatric illness. Some speculations. , 1991, Archives of general psychiatry.
[57] Jun-Feng Wang,et al. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. , 2011, The international journal of neuropsychopharmacology.
[58] V. Parikh,et al. Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. , 2003, Journal of psychiatric research.
[59] Elias S. J. Arnér,et al. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. , 2001, Free radical biology & medicine.
[60] M. Egan,et al. Treatment of tardive dyskinesia with vitamin E. , 1992, The American journal of psychiatry.
[61] T. Kosten,et al. Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia , 2012, Neuropharmacology.
[62] B. Halliwell. Phagocyte-derived reactive species: salvation or suicide? , 2006, Trends in biochemical sciences.
[63] R. Reddy,et al. Antioxidant therapeutics for schizophrenia. , 2011, Antioxidants & redox signaling.
[64] Jeffrey K. Yao,et al. Human plasma glutathione peroxidase and symptom severity in schizophrenia , 1999, Biological Psychiatry.
[65] J. Smythies,et al. Schizophrenia; a new approach. II. Result of a year's research. , 1954, The Journal of mental science.
[66] R. McCreadie,et al. The Nithsdale Schizophrenia Surveys. XIV: Plasma Lipid Peroxide and Serum Vitamin E Levels in Patients with and Without Tardive Dyskinesia, and in Normal Subjects , 1995, British Journal of Psychiatry.
[67] J. Lohr,et al. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. , 1996, The Journal of clinical psychiatry.
[68] I. Altuntaş,et al. Erythrocyte Superoxide Dismutase and Glutathione Peroxidase Activities, and Malondialdehyde and Reduced Glutathione Levels in Schizophrenic Patients , 2000, Clinical chemistry and laboratory medicine.
[69] Jeffrey K. Yao,et al. Oxidative stress in schizophrenia: pathogenetic and therapeutic implications. , 2011, Antioxidants & redox signaling.
[70] A J Cross,et al. Abnormal Involuntary Movements in Schizophrenia: Are They Related to the Disease Process or Its Treatment? Are They Associated with Changes in Dopamine Receptors? , 1982, Journal of clinical psychopharmacology.
[71] S. Aust,et al. Transition metals as catalysts of "autoxidation" reactions. , 1990, Free radical biology & medicine.
[72] Jeffrey K. Yao,et al. Reduced status of plasma total antioxidant capacity in schizophrenia , 1998, Schizophrenia Research.
[73] V. Parikh,et al. Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. , 2007, Journal of psychiatric research.
[74] B. Olas,et al. Isoprostenes as indicators of oxidative stress in schizophrenia , 2009, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[75] T. Shinkai,et al. No association between the Pro197Leu polymorphism in the glutathione peroxidase (GPX1) gene and schizophrenia , 2004, Psychiatric genetics.
[76] W. Glazer,et al. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. , 1993, Archives of general psychiatry.
[77] Young-Min Park,et al. Manganese superoxide dismutase gene Ala–9Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patients , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[78] S. Mukherjee,et al. Elevated Plasma Lipid Peroxides at the Onset of Nonaffective Psychosis , 1998, Biological Psychiatry.
[79] A. Horton,et al. Lipid peroxidation and mechanisms of toxicity. , 1987, Critical reviews in toxicology.
[80] P. Lavori,et al. Long-term treatment effects of vitamin E for tardive dyskinesia , 1998, Biological Psychiatry.
[81] H. Canatan,et al. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder , 2002, Cell biochemistry and function.
[82] X. Zhang,et al. Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms , 2003, Psychiatry Research.
[83] D. Leibfritz,et al. Free radicals and antioxidants in normal physiological functions and human disease. , 2007, The international journal of biochemistry & cell biology.
[84] R. Reddy,et al. Free radical pathology in schizophrenia: a review. , 1996, Prostaglandins, leukotrienes, and essential fatty acids.
[85] M. Keshavan,et al. Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. , 2011, Antioxidants & redox signaling.
[86] A. Ciobica,et al. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics , 2010, Neuroscience Letters.
[87] Jeffrey K. Yao,et al. Abnormal age-related changes of plasma antioxidant proteins in schizophrenia , 2000, Psychiatry Research.
[88] H. Canatan,et al. Association between Ala–9Val polymorphism of Mn-SOD gene and schizophrenia , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[89] J. Coyle,et al. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. , 1998, The American journal of psychiatry.
[90] A. Sarandol,et al. Oxidative–antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: Effects of short term antipsychotic treatment , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[91] Lin He,et al. A meta-analysis of oxidative stress markers in schizophrenia , 2010, Science China Life Sciences.
[92] D. Weinberger. Implications of normal brain development for the pathogenesis of schizophrenia. , 1987, Archives of general psychiatry.
[93] M. Berk,et al. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. , 2008, The international journal of neuropsychopharmacology.
[94] S. Mukherjee,et al. Impaired antioxidant defense at the onset of psychosis , 1996, Schizophrenia Research.
[95] I. Grattagliano,et al. An update on the role of free radicals and antioxidant defense in human disease , 1999, International journal of clinical & laboratory research.
[96] D. Jeste,et al. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia , 1990, Biological Psychiatry.